[Click eStock] "KainosMed, Active Technology Licensing Shows Strong Competitiveness in Parkinson's Disease Treatment"

AIDS Treatment Candidate Completes Phase 3 Clinical Trial in China
Expect NDA Submission in China Next Year

[Asia Economy Reporter Hyungsoo Park] Shinhan Financial Investment evaluated Kainosmed on the 8th, stating that considering the size of the US Parkinson's disease market, its investment attractiveness is high.

Kainosmed merged with Hana Financial 11th SPAC and transferred its listing from the KONEX market to the KOSDAQ market. Kainosmed is developing multiple new drugs centered on the central nervous system (CNS) disease treatment candidate KM-819. The core pipeline is the FAF1 inhibitor KM-819, which is undergoing clinical research targeting Parkinson's disease, multiple system atrophy, and heart failure.

Researcher Donggeon Lee of Shinhan Financial Investment analyzed, "The market capitalization confirmed based on the closing price of Hana Financial 11th SPAC on the last trading day before the merger, the 5th, is 488.2 billion KRW," and added, "Considering the size of the Parkinson's disease market, the investment attractiveness is high."

According to the market research firm GlobalData, the Parkinson's disease treatment market size in the world's seven major countries is expected to grow from $3.1 billion in 2016 to $8.8 billion (approximately 10.6 trillion KRW) in 2026.

Lee advised, "There is a significant difference from the value of 284.1 billion KRW just before trading in the KONEX market, so there is a possibility of short-term profit-taking sales."

Kainosmed is conducting joint research on 'KM-819' with PICC, the only non-profit Parkinson's disease basic research and clinical institution in the United States. They aim to enter Phase 2 clinical trials in the US in the second half of this year.

Lee emphasized, "By conducting joint research with PICC, which has multiple Parkinson's disease-related clinical data and development capabilities, their technology has been recognized," and added, "It is also noteworthy that they secured Phase 2 clinical trial costs from a US bio-specialized investment institution."

He added, "In particular, KM-819 has the potential to be used as a treatment for various diseases such as Parkinson's disease, multiple system atrophy, and heart failure."

Parkinson's disease is a field that global pharmaceutical companies focus on because there is no fundamental cure. This is why technology transfers are active. Lee explained, "In 2019, Voyager Therapeutics licensed a preclinical stage pipeline to AbbVie for $1.5 billion." He continued, "Prothena licensed a Phase 1 pipeline to Roche for $600 million," and emphasized, "Kainosmed has also completed Phase 1 clinical trials and expects to enter Phase 2 within this year."

Lee judged that Kainosmed's competitiveness in the Parkinson's disease treatment development market is sufficient.

Lee also stated, "The administration of the Phase 3 clinical trial for the AIDS treatment candidate KM-023 in China has been completed," and introduced, "Kainosmed's KM-023 is being developed as a Single Tablet Regimen to overcome the shortcomings of existing AIDS treatments."

Furthermore, he predicted, "Submission of the New Drug Application (NDA) in China is expected next year," and added, "Kainosmed will receive a certain royalty from sales after marketing."

This content was produced with the assistance of AI translation services.